BRIEF-Nuvo pharmaceuticals to study Pennsaid 2 pct

Wed Jul 13, 2016 8:43am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 13 (Reuters) - Nuvo Pharmaceuticals Inc

* Nuvo Pharmaceuticals Inc. announces Pennsaid 2 percent phase 3 trial to support regulatory approvals in the E.U., Canada and Australia

* Will conduct a new placebo-controlled, multi-centre phase 3 trial in Germany to study Pennsaid 2 percent for treatment of acute ankle sprains Source text for Eikon: Further company coverage: